Recent News

• 12.07.2025 - Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
• 12.07.2025 - Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
• 11.26.2025 - Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
• 11.26.2025 - Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
• 11.17.2025 - Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
• 11.17.2025 - Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
• 11.12.2025 - Rigel to Present at the Jefferies Global Healthcare Conference in London
• 11.12.2025 - Rigel to Present at the Jefferies Global Healthcare Conference in London
• 11.04.2025 - Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.04.2025 - Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - EX-99.1 EX-99.1
• 11.04.2025 - 8-K Current report
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]